Maze Therapeutics has completed a Series D financing round, raising $115m to propel the development of its lead candidates, MZE829 and MZE782.
The financing round included the conversion of convertible notes previously acquired by existing investors.
Deep Track Capital and Frazier Life Sciences co-led the financing round, with Logos Capital and Janus Henderson Investors also taking part.
Existing investors include ARCH Venture Partners, Third Rock Ventures, GV, Matrix Capital Management, General Catalyst and Woodline Partners.
An oral APOL1 inhibitor, MZE829 is under evaluation as a potential treatment for APOL1 kidney disease, including in individuals with focal segmental glomerulosclerosis.
A Phase II trial is anticipated to commence by the first quarter of next year.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
Maze is also assessing the oral SCL6A19 inhibitor, MZE782, in a Phase I study involving healthy volunteers.
The company has plans to further evaluate this candidate for the treatment of chronic kidney disease and phenylketonuria, with Phase I trial results expected in the second half of 2025.
JP Morgan served as placement agent to Maze during the financing round.
The company continues to advance its pipeline through its Compass platform, which leverages genetic insights to detect biological pathways linked to disease in certain patient groups.
Maze Therapeutics CEO Jason Coloma stated: “We are grateful and honoured to have had the continued support of our long-term investors over the past several years and are thrilled to welcome the Frazier, Deep Track […] and Logos teams as we advance our two lead clinical programmes, MZE829 and MZE782, and continue to leverage our Compass platform.
“The additional resources provided by this financing will allow us to optimise our upcoming Phase II trial of MZE829 and further explore the potential of both lead programmes. This financing marks an important step in our growth as a company, and for the patients we aim to serve.”
In May 2023, the company entered an exclusive worldwide licence agreement with Sanofi for the glycogen synthase 1 (GYS1) programme and MZE001, an oral substrate reduction therapy, aimed at treating Pompe disease.
